SynthesisFrontiers in nutrition2023
Impact of sarcopenia and sarcopenic obesity on survival in patients with primary liver cancer: a systematic review and meta-analysis.
Synthesis in Frontiers in nutrition, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.
- Prognostic and clinicopathological significance of systemic inflammation response index in patients with hepatocellular carcinoma: a systematic review and meta-analysis.Frontiers in immunology · 2024Pooled it
- A clinical-radiomics model based on MRI sub-regions of gluteus maximus for recurrence prediction in high-grade serous ovarian cancer.Abdominal radiology (New York) · 2026Article
- Prognostic value of CT-defined sarcopenic obesity in hepatocellular carcinoma patients undergoing transarterial chemoembolization.BMC gastroenterology · 2026Article
- Prevalence of sarcopenia in patients with surgical obstructive jaundice and its impact on clinical outcomes.World journal of gastrointestinal surgery · 2025Article
- Impact of Preoperative CT-Diagnosed Sarcopenic Obesity on Outcomes After Radical Cystectomy for Bladder Cancer.Cancers · 2025Article
- The alkaline phosphatase-to-prealbumin ratio combined with CT-quantified sarcopenia predicts survival in gastric cancer patients after surgical resection.Frontiers in nutrition · 2025Article
- Imaging-based assessment of muscles and malnutrition predict prognosis in patients with primary hepatocellular carcinoma.PloS one · 2025Article
- Unlocking the future: Machine learning sheds light on prognostication for early-stage hepatocellular carcinoma: Editorial on "Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma".Clinical and molecular hepatology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sarcopenia and sarcopenic obesity are associated with an increased possibility of adverse clinical outcomes; however, the effects of sarcopenia and sarcopenic obesity on patients with primary liver cancer remain controversial. Therefore, the present study aimed to determine the impact of sarcopenia and sarcopenic obesity on survival in patients with primary liver cancer. Methods: We searched studies published in English in PubMed, Embase, Web of Science, and Cochrane Library databases up to 13 November 2022. Cohort studies that reported the association among sarcopenia, sarcopenic obesity, and patient survival were included. Results: A total of 64 cohort studies with data on 11,970 patients with primary liver cancer were included in the meta-analysis. Sarcopenia was associated with poor overall survival in patients with primary liver cancer [adjusted hazard ratio (HR) 2.11, 95% confidence interval (CI): 1.89-2.36, Conclusion: Sarcopenia and sarcopenic obesity were significantly associated with poor overall survival and recurrence-free/disease-free survival in patients with primary liver cancer. Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=378433, PROSPERO [42022378433].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.